Open Access

[Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells

  • Authors:
    • Wei Du
    • Changhe Pang
    • Yake Xue
    • Qingjun Zhang
    • Xinting Wei
  • View Affiliations

  • Published online on: March 15, 2021     https://doi.org/10.3892/ol.2021.12636
  • Article Number: 375
  • Copyright : © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

View Figures

Related Articles

Journal Cover

May-2021
Volume 21 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Du W, Pang C, Xue Y, Zhang Q and Wei X: [Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells. Oncol Lett 21: 375, 2021
APA
Du, W., Pang, C., Xue, Y., Zhang, Q., & Wei, X. (2021). [Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells. Oncology Letters, 21, 375. https://doi.org/10.3892/ol.2021.12636
MLA
Du, W., Pang, C., Xue, Y., Zhang, Q., Wei, X."[Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells". Oncology Letters 21.5 (2021): 375.
Chicago
Du, W., Pang, C., Xue, Y., Zhang, Q., Wei, X."[Corrigendum] Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells". Oncology Letters 21, no. 5 (2021): 375. https://doi.org/10.3892/ol.2021.12636